Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 1046-1058
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.1046
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.1046
Rank | Intervention | SUCRA value |
1 | Neoadjuvant plus adjuvant FLOT | 0.91 |
2 | Neoadjuvant plus adjuvant CF | 0.74 |
3 | Neoadjuvant DCS plus adjuvant S-1 | 0.67 |
4 | Neoadjuvant ECF plus adjuvant ECF and radiotherapy | 0.67 |
5 | Neoadjuvant plus adjuvant DCF | 0.66 |
6 | Neoadjuvant plus adjuvant ECF | 0.65 |
7 | Neoadjuvant plus adjuvant XELOX | 0.57 |
8 | Neoadjuvant SOX and radiotherapy plus adjuvant SOX | 0.46 |
9 | Neoadjuvant CS plus adjuvant S-1 | 0.46 |
10 | Surgery alone | 0.37 |
11 | Neoadjuvant plus adjuvant SOX | 0.28 |
12 | Adjuvant SOX | 0.27 |
13 | Neoadjuvant plus adjuvant FOLFOX | 0.17 |
14 | Adjuvant XELOX | 0.11 |
- Citation: Kuang ZY, Sun QH, Cao LC, Ma XY, Wang JX, Liu KX, Li J. Efficacy and safety of perioperative therapy for locally resectable gastric cancer: A network meta-analysis of randomized clinical trials. World J Gastrointest Oncol 2024; 16(3): 1046-1058
- URL: https://www.wjgnet.com/1948-5204/full/v16/i3/1046.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i3.1046